Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$46.81 USD
-0.75 (-1.58%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $46.82 +0.01 (0.02%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
EXAS 46.81 -0.75(-1.58%)
Will EXAS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAS
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Other News for EXAS
Exact Sciences (EXAS) Receives a Buy from Piper Sandler
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
November 15th Options Now Available For EXACT Sciences (EXAS)
Exact Sciences schedules second quarter 2024 earnings call
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls